Molecular Partners Ag (MOLN) EV to EBITDA (2021 - 2026)
Molecular Partners Ag's (MOLN) quarterly EV to EBITDA came in at 4088.32 in Q2 2026, down 437.82% year-over-year from 1210.22 in Q2 2025, and down 17.64% quarter-over-quarter from 3475.31 in Q1 2026.
Analysis
Molecular Partners Ag (MOLN) EV to EBITDA (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EV to EBITDA for 6 consecutive years, with 4088.32 the latest figure, recorded in Q2 2026.
- On a quarterly basis, EV to EBITDA fell 437.82% year-over-year to 4088.32 in Q2 2026; TTM through Jun 2026 was 0.97, a 524.94% decrease from a year earlier, with the FY2025 full-year figure at 0.91, down 390.63% from the prior year.
- EV to EBITDA was 4088.32 for Q2 2026 at Molecular Partners Ag, down from 3475.31 in the prior quarter.
- Over five years, EV to EBITDA peaked at 5546.56 in Q3 2023 and troughed at 4088.32 in Q2 2026.
- A 5-year average of 270.98 and a median of 0.5 in 2022 frame the typical range for EV to EBITDA.
- Across the five-year window, EV to EBITDA jumped 557.96% in 2023 and plunged 15044.25% in 2025, its largest moves.
- Over 5 years, EV to EBITDA stood at 0.19 in 2022, then surged by 557.96% to 0.85 in 2023, then slumped by 64.7% to 0.3 in 2024, then slumped by 372.27% to 0.82 in 2025, then slumped by 498474.02% to 4088.32 in 2026.
- The last three EV to EBITDA figures came in at 4088.32 (Q2 2026), 3475.31 (Q1 2026), and 0.82 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4,088.32 |
| Mar 31, 2026 | -3,475.31 |
| Dec 31, 2025 | -0.82 |
| Sep 30, 2025 | -1,267.43 |
| Jun 30, 2025 | -760.17 |
| Mar 31, 2025 | -613.09 |
| Dec 31, 2024 | 0.30 |
| Sep 30, 2024 | -1,138.41 |
| Jun 30, 2024 | -5.02 |
| Mar 31, 2024 | 2,576.64 |
| Dec 31, 2023 | 0.85 |
| Sep 30, 2023 | 5,546.56 |
| Jun 30, 2023 | 1.05 |
| Mar 31, 2023 | 2,059.39 |
| Dec 31, 2022 | -0.19 |
| Sep 30, 2022 | 3,981.34 |
| Jun 30, 2022 | -15.24 |
| Mar 31, 2022 | 2,075.43 |
| Dec 31, 2021 | -6.92 |
| Sep 30, 2021 | -28,865.37 |